Skip to main content
FinSpry Logo
FinSpry
AUPH logo
AUPH
(NASDAQ)
Aurinia Pharmaceuticals Inc.
$15.61-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Aurinia Pharmaceuticals (AUPH) Stock Price & Financial Analysis

Aurinia Pharmaceuticals Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$15.05 - $15.69
52-Week High$16.54
52-Week Low$6.83
Open$15.20
Volume1.26M
Average Volume (3M)1.26M
Market Cap2.17B
Shares Outstanding138.70M
P/E Ratio (TTM)7.47
Forward P/E3.74
Price to Sales (P/S)7.58
Price to Book (P/B)3.69
EV/EBITDA14.92
Revenue (TTM)283.06M
Net Income (TTM)287.20M
Free Cash Flow (TTM)134.31M
EPS (TTM)$2.07
Profit Margin101.47%
Operating Margin37.65%
Return on Equity (ROE)49.40%
Debt to Equity0.13
50-Day MA$14.49
200-Day MA$12.97
52-Week Change92.17%
Annual Dividend$0.00
Dividend Yield0.00%
Payout Ratio0.00%

Frequently Asked Questions About Aurinia Pharmaceuticals

What is the current stock price for AUPH?

As of the latest trading session, AUPH stock trades at $15.61. The 52-week range is $6.83–$16.54, with a day range of $15.05–$15.69.

What is the P/E ratio for AUPH?

Aurinia Pharmaceuticals's trailing P/E ratio is 7.5, meaning investors pay $7.5 for every $1 of annual earnings. The forward P/E is 3.7, reflecting analyst expectations for future earnings. Aurinia Pharmaceuticals operates in the Healthcare sector.

Does AUPH pay dividends?

Aurinia Pharmaceuticals does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for AUPH?

Analyst ratings and recommendations for AUPH are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.

What is the market cap of AUPH?

Aurinia Pharmaceuticals's market capitalization is $2.17B, classifying it as a mid-cap company. Aurinia Pharmaceuticals operates in the Healthcare sector within the Biotechnology industry.